Tags: MDMAecstasyPTSD therapydenverdenver botanic garden
| Profile | Contacts | Recent Articles on Subject | |
|---|---|---|---|
| 1 | Nicoletta Lanese Live Science Science journalist. New York, USA | ||
| 2 | John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California | ||
| 3 | Meagan Parrish Pharma Voice Senior editor @industrydive.
Pharma world follower. Wisconsin, USA | ||
| 4 | Oshan Jarow Vox Focus on consciousness, economics. Co-founder LE Possibility. Brooklyn, New York | Nitrous, one of the oldest mind-altering drugs, is back - 5 months ago MDMA therapy didn’t get FDA approval. Now what? - 7 months ago | |
| 5 | Carly Cassella Science Alert Writer at ScienceAlert. | ||
| 6 | Andrew Paul Popular Science Now on Bluesky America's Heartland | ||
| 7 | Kristen Monaco MedPage Today | FDA Rejects MDMA-Assisted Therapy for PTSD - 7 months ago MDMA for PTSD Under FDA Review; GLP-1 for Opioid Cravings; ADHD an Evolutionary Aid? - about 1 year ago Psychedelics for Psych Conditions Made Their Mark in 2023 - about 1 year ago | |
| 8 | Marissa Plescia MedCity News Reporter at MedCity News. | What’s Next for Psychedelic Medicines? - 4 months ago | |
| 9 | Sophie Putka MedPage Today Enterprise, investigative writer. New York, USA | ||
| 10 | Meghana Keshavan STAT News Biotech nerd and writer @statnews. | STAT+: Rick Doblin, ‘unleashed,’ blasts FDA over Lykos drug rejection and turns to global push for MDMA therapy - 6 months ago A tough week for MDMA-assisted psychotherapy - 6 months ago FDA rejects MDMA as a psychedelic treatment for PTSD - 7 months ago Psychedelic investment continues to ramp up - about 1 year ago |